Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo-controlled study

Journal of Hepatology

Volumn 25, Issue 5, 1996, Pages 591-598

  Dusheiko, Geoffrey ^e   Main, Janice ^f   Thomas, Howard ^f   Reichard, Olle ^a   Lee, Christine ^f   Dhillon, Amar ^f   Rassam, Suhra ^f   Fryden, Aril ^b   Reesink, Henk ^f   Bassendine, Margaret ^f   Norkrans, Gunnar ^c   Cuypers, Theo ^f   Lelie, Nico ^f   Telfer, Paul ^f   Watson, Jon ^f   Weegink, Christine ^f   Sillikens, Peter ^f   Weiland, Ola ^d  

^a DANDERYD HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e ROYAL FREE HOSPITAL   (United Kingdom)

^f NONE

Author keywords

Antivirals; Chronic hepatitis; Hepatitis C antiviral therapy; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; PLACEBO; RIBAVIRIN;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENOTYPE; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HISTOLOGY; HUMAN; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS HEPATITIS;

EID: 10344259671     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(96)80225-X     Document Type: Article

References (23)

1. 1. Colombo M, Kuo G, Choo Q, Donate M, Del-Ninno E, Tommasini M, Dioguardi N, Houghton M. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989; ii: 1006-8.
2. 2. Bruix J, Barrera JM, Calvet X, Ercilla G, Costa J, Sanchez-Tapias JM, Ventura M, Vall M, Bruguera M, Bru C, Castillo R, Rodés J. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989; ii: 1004-6.
3. 3. Realdi G, Alberti A, Rugge M, Rigoli AM, Tremolada F, Schivapazza L, Ruol A. Long-term follow-up of acute and chronic non-A non-B hepatitis: evidence of progression to liver cirrhosis. Gut 1982; 23: 270-5.
4. 4. Di-Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofnagle JH. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321: 1506-10.
5. 5. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HCJ, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, Van Thiel DH, Tamburro C, Lefkowitch T, Albrecht J, Meschievitz C, Ortego T, Gibas A, and the Hepatitis Interventional Therapy Group. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989; 321: 1501-6.
6. 6. Sidwell R, Huffman JH, Khare L, Allen LB, Witlowski JT, Robins RK. Broad-spectrum activity of virazole: 1-beta-Dribofuranosyl-1,2,4-triazole-3-carboxamide. Science 1972; 117: 705-6.
7. 7. Di Bisceglie AM, Shindo M, Fong T-L, Fried MW, Swain MG, Bergasa NV, Axiotis CA, Waggoner JG, Park Y, Hoofnagle JH. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 1992; 16: 649-54.
8. 8. Reichard O, Andersson J, Schvarcz R, Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet 1991; 337: 1058-61.
9. 9. Reichard O, Yun Z-B, Sönnerborg A, Weiland O. Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C. J Med Virol 1993; 41: 99-102.
10. 10. Urdea MS. Synthesis and characterization of branched DNA (bDNA) for the direct and quantitative detection of CMV, HBV, HCV, and HIV. Clin Chem 1993; 39: 725-6.
11. 11. Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, Van Heuverswyn H, Maertens G. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993; 74: 1093-102.
12. 12. Dusheiko G, Simmonds P. Sequence variability of hepatitis C virus and its clinical relevance. J Viral Hep 1994: 1: 3-15.
13. 13. Simmonds P. Variability of hepatitis C virus. Hepatology 1995; 21: 570-83.
14. 14. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis Hepatology 1981; 1: 431-5.
15. 15. Hagiwara H, Hayashi N, Mita E, Ueda K, Takehara T, Kasahara A, Fusamoto H, Kamada T. Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-α. Hepatology 1992; 15: 37-41.
16. 16. Chayama K, Saitoh S, Arase Y, Ikeda K, Matsumoto T, Sakai Y, Kobayashi M, Unakami M, Morinaga T, Kumada H. Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C. Hepatology 1991; 13: 1040-3.
17. 17. Brillanti S, Garson JA, Tuke PW, Ring C, Briggs M, Masci C, Miglioli M, Barbara L, Tedder RS. Effect of α-interferon therapy on hepatitis C viraemia in community-acquired chronic non-A, non-B hepatitis: a quantitative polymerase chain reaction study. J Med Virol 1991; 34: 136-41.
18. 18. Shindo M, Di-Bisceglie AM, Cheung L, Shih JW, Cristiano K, Feinstone SM, Hoofnagle JH. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med 1991; 115: 700-4.
19. 19. Kanai K, Kako M, Okamoto H. HCV genotypes in chronic hepatitis C and response to interferon. Lancet 1992; 339: 1543.
20. 20. Okada S, Akahane Y, Suzuki H, Okamoto H, Mishiro S. The degree of variability in the amino terminal region of the E2/ NS 1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 1992; 16: 619-4.
21. 21. McOmish F, Chan S-W, Dow BC, Gillon J, Frame WD, Crawford RJ, Yap P-L, Follett EAC, Simmonds P. Detection of three types of hepatitis C virus in blood donors: investigation of type-specific differences in serologic reactivity and rate of alanine aminotransferase abnormalities. Transfusion 1993; 33: 7-13.
22. 22. Simmonds P, Holmes EC, Cha T-A, Chan S-W, McOmish F. Irvine B, Beall E, Yap PL, Kolberg J, Urdea MS. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993; 74: 2391-9.
23. 23. Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, Miglioli M, Barbara L. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 1994; 107: 812-7.